Celgene (NASDAQ:CELG) received a $166.00 price objective from investment analysts at Oppenheimer in a report issued on Friday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Oppenheimer’s price objective points to a potential upside of 56.41% from the company’s current price.
A number of other equities analysts also recently issued reports on the company. Credit Suisse Group set a $123.00 price objective on Celgene and gave the stock a “buy” rating in a report on Friday. Stifel Nicolaus decreased their price objective on Celgene from $149.00 to $130.00 and set a “buy” rating for the company in a report on Friday. Cantor Fitzgerald set a $112.00 price objective on Celgene and gave the stock a “hold” rating in a report on Thursday. Vetr downgraded Celgene from a “strong-buy” rating to a “buy” rating and set a $121.72 price objective for the company. in a report on Monday. Finally, Leerink Swann reiterated a “buy” rating and issued a $120.00 price objective on shares of Celgene in a report on Wednesday, December 13th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $135.43.
Shares of Celgene (NASDAQ CELG) traded down $1.75 during mid-day trading on Friday, reaching $106.13. The company had a trading volume of 4,662,913 shares, compared to its average volume of 4,814,450. Celgene has a 12 month low of $94.55 and a 12 month high of $147.17. The stock has a market capitalization of $84,940.00, a price-to-earnings ratio of 16.92, a price-to-earnings-growth ratio of 0.84 and a beta of 1.77. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52.
In other news, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction on Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the transaction, the insider now directly owns 3,925 shares in the company, valued at $564,768.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.95% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Thompson Davis & CO. Inc. increased its holdings in Celgene by 5.9% in the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 43 shares in the last quarter. Arcadia Investment Management Corp MI boosted its position in Celgene by 118.7% in the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 400 shares during the last quarter. Robecosam AG purchased a new position in Celgene in the third quarter worth about $114,000. Guidant Wealth Advisors purchased a new position in Celgene in the third quarter worth about $119,000. Finally, Capital Bank & Trust Co boosted its position in Celgene by 166.8% in the third quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 517 shares during the last quarter. Institutional investors own 79.84% of the company’s stock.
About Celgene
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
